Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology

被引:49
作者
Hendrickx, G. [1 ]
Van Herck, K.
Vorsters, A.
Wiersma, S. [2 ]
Shapiro, C. [3 ]
Andrus, J. K. [4 ]
Ropero, A. M. [4 ]
Shouval, D. [5 ]
Ward, W. [2 ]
Van Damme, P.
机构
[1] Univ Antwerp, Fac Med, Vaccine & Infect Dis Inst, Ctr Evaluat Vaccinat, B-2160 Antwerp, Belgium
[2] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA
[3] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland
[4] Pan Amer Hlth Org, Washington, DC USA
[5] Hadassah Hebrew Univ Hosp, Liver Unit, Jerusalem, Israel
关键词
global hepatitis A meeting; hepatitis A; hepatitis A vaccination; infectious disease control; public health; surveillance;
D O I
10.1111/j.1365-2893.2008.01022.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
For the first time a global meeting on hepatitis A virus (HAV) infection as vaccine preventable disease was organized at the end of 2007. More than 200 experts from 46 countries gathered to investigate the changing global HAV epidemiology reflecting the increasing numbers of persons at risk for severe clinical disease and mortality from HAV infection. The benefits of childhood and adult hepatitis A (HepA) vaccination strategies and the data needed by individual countries and international health organizations to assess current HepA prevention strategies were discussed. New approaches in preventing HAV infection including universal HepA vaccination were considered. This introductory paper summarizes the major findings of the meeting and describes the changing epidemiology of HAV infections and the impact of HepA vaccination strategies in various countries. Implementation of HepA vaccination strategies should take into account the level of endemicity, the level of the socio-economic development and sanitation, and the risk of outbreaks. A stepwise strategy for introduction of HepA universal immunisation of children was recommended. This strategy should be based on accurate surveillance of cases and qualitative documentation of outbreaks and their control, secure political support on the basis of high-quality results, and comprehensive cost-effectiveness studies. The recognition of the need for increased global attention towards HepA prevention is an important outcome of this meeting.
引用
收藏
页码:1 / 15
页数:15
相关论文
共 41 条
[1]  
Ambrosch F, 2004, INFECTION, V32, P249, DOI 10.1007/s15010-004-9404-8
[2]  
Andrus JK, 2007, PUBLIC HEALTH REP, V122, P811
[3]   Cost-effectiveness analyses of hepatitis a vaccine - A systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies [J].
Anonychuk, Andrea M. ;
Tricco, Andrea C. ;
Bauch, Chris T. ;
Pham, Ba' ;
Gilca, Vladimir ;
Duval, Bernard ;
John-Baptiste, Ava ;
Woo, Gloria ;
Krahn, Murray .
PHARMACOECONOMICS, 2008, 26 (01) :17-32
[4]   The economics of routine childhood hepatitis A immunization in the United States: The impact of herd immunity [J].
Armstrong, Gregory L. ;
Billah, Kaafee ;
Rein, David B. ;
Hicks, Katherine A. ;
Wirth, Kathleen E. ;
Bell, Beth P. .
PEDIATRICS, 2007, 119 (01) :E22-E29
[5]   Cost-utility of universal hepatitis A vaccination in Canada [J].
Bauch, C. T. ;
Anonychuk, A. M. ;
Pham, B. Z. ;
Gilca, V. ;
Duval, B. ;
Krahn, M. D. .
VACCINE, 2007, 25 (51) :8536-8548
[6]   Successful booster antibody response up to 54 months after single primary vaccination with virosome-formulated, aluminum-free hepatitis A vaccine [J].
Beck, BR ;
Hatz, C ;
Brönnimann, R ;
Herzog, C .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (09) :E126-E128
[7]   Economic evaluation of vaccination programmes -: A consensus statement focusing on viral hepatitis [J].
Beutels, P ;
Edmunds, WJ ;
Antoñanzas, F ;
De Wit, GA ;
Evans, D ;
Feilden, R ;
Fendrick, AM ;
Ginsberg, GM ;
Glick, HA ;
Mast, E ;
Péchevis, M ;
Van Doorslaer, EKA ;
van Hout, BA .
PHARMACOECONOMICS, 2002, 20 (01) :1-7
[8]   Long-term immunogenicity of an inactivated virosome hepatitis A vaccine [J].
Bovier, PA ;
Bock, J ;
Loutan, L ;
Farinelli, T ;
Glueck, R ;
Herzog, C .
JOURNAL OF MEDICAL VIROLOGY, 2002, 68 (04) :489-493
[9]   Rapid protection and vaccination against hepatitis A for travellers [J].
Connor, BA ;
Van Herck, K ;
Van Damme, P .
BIODRUGS, 2003, 17 (Suppl 1) :19-21
[10]   Incidence of hepatitis A in Israel following universal immunization of toddlers [J].
Dagan, R ;
Leventhal, A ;
Anis, E ;
Slater, P ;
Ashur, Y ;
Shouval, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (02) :202-210